Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL186143 | 0.84 | MEN1 (0.36) | MEN1KMT2AALDH1A1NPC1TP53 | |
| SCHEMBL2303328 | 0.80 | KMT2A (0.35) | MEN1KMT2AALDH1A1NPC1TP53 | |
| SCHEMBL186509 | 0.79 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL10197050 | 0.79 | MEN1 (0.32) | MEN1KMT2A | |
| SCHEMBL6469034 | 0.79 | MEN1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL186524 | 0.78 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL6468977 | 0.78 | MEN1 (0.41) | MEN1KMT2A | |
| SCHEMBL6256558 | 0.78 | MEN1 (0.36) | MEN1KMT2ANPC1RAB9A | |
| SCHEMBL9732458 | 0.78 | MEN1 (0.41) | MEN1KMT2AALDH1A1CPB2 | |
| SCHEMBL7087522 | 0.78 | MEN1 (0.32) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084498-B2 | Ketone compounds and compositions for cholesterol management and related uses | ESPERION THERAPEUTICS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20100137444-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS, INC. | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137444-A1 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | PC, HMGCR, GPR119 | MEN1 1965/4885KMT2A 1684/4885ALDH1A1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.